Is total hip arthroplasty safely performed in lung transplant patients? Current experience from a retrospective study of the Zurich lung transplant cohort

Table 1 Patient characteristics

Patient	Sex	Age y	Joint indication	Approach	Immunosuppression	Antibiotic prophylaxis	Hospital stay d	Interval y	F/U y	Subjective hip value %	Harris Hip Score (HHS) points	Perioperative complications	Prosthetic complications
MJ	f	47	Posttraumatic AVN	Hardinge	CYA, MMF, PRED	CIP	7	11.0	11.1	90	86	None	None
SB	f	42	AVN	Hardinge	CYA, MMF, PRED	TZP, TEC, CIP	39	12.2	3.1	100	100	Wound healing disturbance	None
SS	m	23	Posttraumatic AVN	Hardinge	CYA, MMF, PRED	TEC, MER (INN)	16	9.4	2.0	100	97	None	None
MH	f	62	Pathologic Fx	AMIS	CYA, MMF, PRED	TZP, TEC, CIP	11	3.1	2.6	90	100	None	None
FS	f	68	AVN	AMIS	CYA, MMF, PRED	TZP, TEC	8	2.4	2.0	100	95	None	None

AVN Avascular necrosis, Fx Fracture, Hardinge Hardinge approach, AMIS Anterior minimal invasive surgery – modified Hueter approach, CYA Cyclosporine A, TAC Tacrolimus, MMF Mycophenolate Mofetil, PRED Prednisone, CIP Ciprofloxacin, MER Meropenem, TEC Teicoplanin, TZP Piperacillin/Tazobactam, INN Amoxicillin/Clavulanic acid, Interval Time from lung transplantation to total hip arthroplasty, F/U Follow-up time

ISSN: 1754-9493